Esperite NV represents values of innovation, scientific excellence, and commitment to improving healthcare solutions. With a strong corporate philosophy centered around pioneering stem cell technologies, Esperite NV is dedicated to unlocking the therapeutic potential of stem cells for regenerative medicine. By leveraging its extensive expertise in cryopreservation and biomedical services, the company aims to empower patients and healthcare professionals with state-of-the-art tools for personalized medicine. Esperite NV's commitment to quality, safety, and ethical practices resonates throughout its operations, ensuring the utmost integrity in delivering advanced healthcare solutions.

Esperite NV, a renowned company in the stock market, primarily operates in various countries and regions. It has a significant presence in the European market, with a focus on countries such as the Netherlands, Spain, Belgium, and the United Kingdom. Additionally, Esperite NV extends its reach to key regions including the Middle East and North Africa. With its diversified portfolio and strategic partnerships, Esperite NV has established a strong foothold in these regions, allowing it to cater to a wide range of investors and stakeholders.

Esperite NV, a renowned company in the stock market, has achieved several significant milestones. Over the years, Esperite NV has successfully expanded its global presence, establishing a strong foothold in the field of cell therapy and biobanking. With strategic partnerships and collaborations with industry leaders, Esperite NV has propelled innovation and advancements in stem cell research. Additionally, the company has consistently delivered breakthrough technologies, contributing to the development of groundbreaking medical solutions. Esperite NV's commitment to excellence and dedication to its stakeholders have led to consistent growth and enhanced shareholder value, making it a leading player in the stock market.

Esperite NV is a company with a rich history and background. Established in 2000, Esperite NV, formerly known as Cryo-Save Group NV, is a leading biotech company specializing in the collection, processing, and storage of stem cells obtained from umbilical cord blood and tissue. The company has an extensive global presence, operating multiple cryopreservation and processing laboratories across Europe and South Africa. Through its subsidiary, Cryo-Save, Esperite NV has successfully stored over 325,000 samples, providing families with a valuable resource for future medical treatments. With a strong commitment to research and innovation, Esperite NV continues to contribute significantly to the advancement of regenerative medicine and stem cell-based therapies.

Esperite NV faces competition from several companies in the market. Some of its main competitors include Cryo-Save Group, StemCare, and FamilyCord. These companies also operate in the field of stem cell banking and offer similar services. However, Esperite NV distinguishes itself through its innovative technology and extensive global presence. It strives to maintain a competitive edge by continuously advancing its product offerings and expanding its customer base.

Esperite NV is primarily active in the healthcare industry.

The business model of Esperite NV focuses on offering innovative solutions in the field of biotechnology, particularly in the area of stem cells. Esperite NV, a company based in the Netherlands, is dedicated to the development and commercialization of advanced therapies for regenerative medicine, cellular therapy, and personalized medicine. This includes the collection, processing, storage, and distribution of stem cells from multiple sources, such as umbilical cord blood and tissue. By leveraging their expertise and partnerships, Esperite NV aims to provide valuable medical services and products that contribute to improving patient outcomes and healthcare advancements.

The P/E ratio cannot be calculated for Esperite at the moment.

The P/S cannot be calculated for Esperite currently.

The Quality Investing for Esperite is 3/10.

The revenue cannot currently be calculated for Esperite.

The profit cannot currently be calculated for Esperite.

Esperite NV is a Dutch company specializing in life sciences. It operates a diversified business model consisting of various divisions to achieve its goals in research and development and the provision of services to the medical industry. The company's primary division is the biological cell banking unit, operating under the brand name CryoSave. CryoSave collects stem cells from umbilical cord blood and tissue, dental pulp, milk teeth, adipose tissue, and other tissues with high healing potential. These stem cells are used in the treatment of diseases such as diabetes, cancer, neurological disorders, and other serious conditions. The company also operates the Progenity AB division, a biotech company specializing in the development and production of solutions for cell transfection and culture. Progenity AB also provides services for in vitro research, such as cell line development, cell culture provision, and management. Esperite NV also operates the DNA amplification division, operating under the brand name LifeCode. LifeCode is a leading provider of DNA amplification solutions for the forensic, medical, and scientific community. LifeCode's solutions include reagents and instruments for polymerase chain reaction (PCR) and other amplification and sequencing technologies. Additionally, the company is also involved in the field of animal health, particularly in cattle breeding. Esperite NV's animal health division operates under the name Cryo-Save Agro, providing leading services in cattle semen and genetic advisory services to breeders. In addition to its businesses in biological research and development, Esperite NV is also involved in clinical trials. The company provides services for the planning of clinical trials, development of protocols, and data management for studies. Esperite NV also operates a charity organization, the Cord for Life Foundation, which functions as a nonprofit organization collecting funds for charitable purposes to support stem cell research and development and promote public awareness of the benefits of stem cell therapies. In summary, Esperite NV operates a diverse business model focusing on the research and development of biological solutions and services. With its divisions in biological cell banking, cell transfection and culture, DNA amplification, animal health, and clinical trials, the company offers a wide range of products and services to its customers, contributing to the advancement of science in the field of regenerative medicine and driving progress in the medical industry.

Esperite pays a dividend of 0 EUR distributed over payouts per year.

The dividend cannot currently be calculated for Esperite or the company does not pay out a dividend.

The ISIN of Esperite is NL0009272137.

The ticker of Esperite is ESP.AS.

Over the past 12 months, Esperite paid a dividend of 0.08 EUR . This corresponds to a dividend yield of about 869.57 %. For the coming 12 months, Esperite is expected to pay a dividend of 0 EUR.

The current dividend yield of Esperite is 869.57 %.

Esperite pays a quarterly dividend. This is distributed in the months of .

Esperite paid dividends every year for the past 0 years.

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

Esperite is assigned to the 'Health' sector.

To receive the latest dividend of Esperite from 6/14/2012 amounting to 0.08 EUR, you needed to have the stock in your portfolio before the ex-date on 5/18/2012.

The last dividend was paid out on 6/14/2012.

In the year 2024, Esperite distributed 0 EUR as dividends.

The dividends of Esperite are distributed in EUR.